WENDY GAMMON: Open Payments
NPI 1669848156 · TEXARKANA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$283 in 15 payments from 10 companies in 2025. Trend: 2023 $531 · 2024 $644 · 2025 $283
Food & beverage: $283
| Company | Payments | Amount |
|---|---|---|
| Currax Pharmaceuticals LLC | 3 | $50 |
| Novo Nordisk Inc | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| ABBVIE INC. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| PFIZER INC. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: CONTRAVE, Wegovy, CAPLYTA, MOUNJARO, VRAYLAR, Auvelity, COBENFY, ELIQUIS.
Industry payments across AR — which companies pay providers there.
